Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer

Enfortumab vedotin and erdafitinib have specific toxicities that need careful management in order to optimise drug exposure while maintaining patients’ quality of life. Patient education, meticulous monitoring, and a multidisciplinary approach are key to optimising outcomes so that patients can reap...

Full description

Saved in:
Bibliographic Details
Published inEuropean urology focus Vol. 10; no. 2; pp. 222 - 223
Main Authors McInerney, Samuel, Jones, Robert J.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.03.2024
Subjects
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Humans
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Quality of Life
Quinoxalines - adverse effects
Quinoxalines - therapeutic use
Urinary Bladder Neoplasms - drug therapy
Online AccessGet full text

Cover

More Information
Summary:Enfortumab vedotin and erdafitinib have specific toxicities that need careful management in order to optimise drug exposure while maintaining patients’ quality of life. Patient education, meticulous monitoring, and a multidisciplinary approach are key to optimising outcomes so that patients can reap the benefits of these new treatments.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2405-4569
2405-4569
DOI:10.1016/j.euf.2024.05.012